JP2019510001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510001A5 JP2019510001A5 JP2018544185A JP2018544185A JP2019510001A5 JP 2019510001 A5 JP2019510001 A5 JP 2019510001A5 JP 2018544185 A JP2018544185 A JP 2018544185A JP 2018544185 A JP2018544185 A JP 2018544185A JP 2019510001 A5 JP2019510001 A5 JP 2019510001A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- use according
- item
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022023843A JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298366P | 2016-02-22 | 2016-02-22 | |
| US62/298,366 | 2016-02-22 | ||
| PCT/US2017/018938 WO2017147182A1 (en) | 2016-02-22 | 2017-02-22 | Actrii antagonists for use in increasing immune activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023843A Division JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510001A JP2019510001A (ja) | 2019-04-11 |
| JP2019510001A5 true JP2019510001A5 (https=) | 2020-04-09 |
| JP7058606B2 JP7058606B2 (ja) | 2022-04-22 |
Family
ID=59629767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544185A Expired - Fee Related JP7058606B2 (ja) | 2016-02-22 | 2017-02-22 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
| JP2022023843A Pending JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023843A Pending JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20170240639A1 (https=) |
| EP (1) | EP3420002A4 (https=) |
| JP (2) | JP7058606B2 (https=) |
| KR (1) | KR20180128405A (https=) |
| CN (1) | CN109311998A (https=) |
| AU (1) | AU2017222526A1 (https=) |
| CA (1) | CA3014197A1 (https=) |
| WO (1) | WO2017147182A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| CA3039573A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
| NZ754161A (en) | 2016-11-10 | 2025-11-28 | Keros Therapeutics Inc | Activin receptor type iia variants and methods of use thereof |
| EP3576773B1 (en) * | 2017-02-01 | 2023-10-18 | Acceleron Pharma Inc. | Tgf beta and actrii antagonists for use in treating leukemia |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN108129572B (zh) * | 2018-01-04 | 2021-01-29 | 河南大学 | 人GDF11-Fc融合蛋白在治疗溃疡性结肠炎中的应用 |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| CA3103427A1 (en) * | 2018-06-15 | 2019-12-19 | Acceleron Pharma Inc. | Bi-and tri-functional fusion proteins and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP7669291B2 (ja) * | 2019-05-30 | 2025-04-28 | アクセレロン ファーマ インコーポレーテッド | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
| CA3153062A1 (en) | 2019-09-03 | 2021-03-11 | Novartis Ag | Treatment of liver disease or disorder comprising actrii receptor antagonists |
| AU2020364139A1 (en) * | 2019-10-10 | 2022-05-26 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modified stem cells and methods of use thereof |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2021189019A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| TW202328190A (zh) * | 2021-09-03 | 2023-07-16 | 大陸商來凱醫藥科技（上海）有限公司 | 抗acvr2a抗體及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009008222A (es) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
| AU2010282361B2 (en) * | 2009-08-13 | 2015-03-19 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
| EP3202459B1 (en) * | 2009-09-09 | 2021-04-14 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| KR101461706B1 (ko) | 2011-04-04 | 2014-11-18 | 한국생명공학연구원 | Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제 |
| WO2013063536A1 (en) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| GR1007832B (el) | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| NZ703724A (en) * | 2012-06-11 | 2017-06-30 | Amgen Inc | Dual receptor antagonistic antigen-binding proteins and uses thereof |
| WO2014172448A2 (en) | 2013-04-17 | 2014-10-23 | Anaptysbio, Inc. | Antibodies directed against activin receptor type ii (actrii) |
| PE20170471A1 (es) * | 2014-06-13 | 2017-05-14 | Santa Maria Biotherapeutics Inc | Polipeptidos receptores formulados y metodos relacionados |
| WO2016090035A2 (en) | 2014-12-02 | 2016-06-09 | La Jolla Institute For Allergy And Immunology | Modulators of activin and methods for modulating immune responses and t follicular helper cells |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
-
2017
- 2017-02-22 US US15/439,386 patent/US20170240639A1/en not_active Abandoned
- 2017-02-22 CA CA3014197A patent/CA3014197A1/en active Pending
- 2017-02-22 CN CN201780024969.4A patent/CN109311998A/zh active Pending
- 2017-02-22 EP EP17757142.9A patent/EP3420002A4/en active Pending
- 2017-02-22 JP JP2018544185A patent/JP7058606B2/ja not_active Expired - Fee Related
- 2017-02-22 KR KR1020187027012A patent/KR20180128405A/ko not_active Abandoned
- 2017-02-22 WO PCT/US2017/018938 patent/WO2017147182A1/en not_active Ceased
- 2017-02-22 AU AU2017222526A patent/AU2017222526A1/en not_active Abandoned
-
2022
- 2022-02-18 JP JP2022023843A patent/JP2022062277A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510001A5 (https=) | ||
| Jiang et al. | cGAS-STING, an important pathway in cancer immunotherapy | |
| Elster et al. | HER2-family signalling mechanisms, clinical implications and targeting in breast cancer | |
| Duffy et al. | Immunological off-target effects of standard treatments in gastrointestinal cancers | |
| Duarte et al. | Gastric cancer: basic aspects | |
| Dasanu et al. | Immune alterations and emerging immunotherapeutic approaches in lung cancer | |
| Goel et al. | Cancer immunotherapy in clinical practice—the past, present, and future | |
| Marelli et al. | A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer | |
| Luedke et al. | Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation | |
| Goldberg et al. | Enhancing cancer immunotherapy via activation of innate immunity | |
| Wahid et al. | An overview of cancer immunotherapeutic strategies | |
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| Kersh et al. | Targeted therapies: immunologic effects and potential applications outside of cancer | |
| Zibelman et al. | Overview of current treatment options and investigational targeted therapies for locally advanced squamous cell carcinoma of the head and neck | |
| Lam et al. | Refractory metastatic colorectal cancer: current challenges and future prospects | |
| JP2021534094A (ja) | 未分化リンパ腫キナーゼ阻害剤と組み合わせてｅｇｆ／ｅｇｆｒ経路を抑制するための方法および組成物 | |
| Rekers et al. | Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives | |
| JP7148399B2 (ja) | 悪性疾患に対する併用療法 | |
| CN109963581A (zh) | 一种il-15蛋白复合物药物组合物及其用途 | |
| AU2020241963A1 (en) | Treatment of cancers using sEphB4-HSA fusion proteins | |
| JP2018509423A5 (https=) | ||
| Bai et al. | Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer | |
| Hwang et al. | Emerging egfr-targeted therapy in head and neck cancer: A review | |
| Terrero et al. | Role of immunotherapy in advanced gastroesophageal cancer | |
| CN105407916A (zh) | 二价疫苗组合物以及其用于治疗肿瘤的用途 |